[Animal experiments of immunotherapy with ovarian tumor vaccine during lymphopenia induced by chemotherapy.].
OBJECTIVE
To explore the mechanisms and effects of adoptive immunotherapy with ovarian cancer vaccine modified by GM-CSF gene which was used after immunologic reconstitution during lymphopenia induced by chemotherapy.


METHODS
Lymphopenia was induced by chemotherapy with cyclophosphamide. The immune reconstituted model was built in rats. The tumor vaccine draining lymph nodes were harvested after the ovarian cancer cells NUTU-19 modified by GM-CSF gene were injected. The effector T cells (T(E)) were got after being stimulated and amplified. Enzyme-linked immunosorbent assay was used to detect the level of interleukin (IL)-2 and IL-4 secreted by T(E). Intracellular cytokine staining was used to determine frequency of tumor-specific T(E). Fluorescence-activated cell sorting (FACS) was used to detect the special cytotoxicity of T(E) killing target cells. The survival period of rats bearing pre-established abdominal ovariam carcinoma after being adoptively transferred by T(E) was observed.


RESULTS
Compared with those in control group, the significant higher levels IL-2 [(65.7 +/- 4.0) pg/ml] and lower levels IL-4 [(277 +/- 49) pg/ml] were observed in chemotherapy-immune reconstitution-vaccine immunization group. The amount of CD(4)(+) T cells secreting interferon-gamma (13.0 +/- 2.1)% were also significantly increased. The rate of the special cytotoxicity of killing T cells (86.5 +/- 1.1)% was markedly improved. The survival period of rats (110 +/- 16) days was increased in chemotherapy-immune reconstitution-vaccine immunization group.


CONCLUSIONS
The combined immunotherapy of chemotherapy-immune reconstitution-tumor vaccine immunotherapy may increase the frequency and function of specific tumor T(E). The specific cytotoxicity is increased and the weak reaction of T(E) to tumor is improved, which showed that this therapy can enhance immune reaction.
Li
Qi-Ling
QL
Department of Obstetrics and Gynecology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
Wang
Yun-Ping
YP
Gao
Shang-Feng
SF
Ma
Jun
J
Feng
Cai-Xia
CX
Wang
Yue-Ling
YL
D032761:Animal Experimentation; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2; D008231:Lymphopenia; D010051:Ovarian Neoplasms / Q000188:drug therapy
D019496:Cancer Vaccines; D007376:Interleukin-2